JaLCDOI 10.18926/AMO/48266
フルテキストURL 66_2_163.pdf.pdf
著者 Utsumi, Hiroya| Cabergoline as the Starting Treatment and its Long-term Effects (CASTLE) Study Group|
抄録 Several international studies have suggested that treatment of early Parkinsonʼs disease (PD) with a dopamine agonist instead of levodopa delays the occurrence of motor complications. This 5-year prospective, open, multicenter randomized study aimed to compare the effects of cabergoline on the onset of motor complications with those of levodopa in Japanese patients with early PD. Patients who had never been treated with dopamine agonists or levodopa were enrolled in this study. Four of 45 patients in the cabergoline group and 11 of 46 patients in the levodopa group developed motor complications. The estimated cumulative incidence of motor complications in the cabergoline and levodopa groups was 17オ and 34オ (hazard ratio, 0.57;95オ confidence interval, 0.18‒1.81;p=0.347). Thirty-five adverse events (AEs) were reported in 24 patients in the cabergoline group, while 16 AEs were reported in 13 patients in the levodopa group. Patients in the cabergoline group showed fewer motor complications than did those in the levodopa group, although the difference was not statistically significant. However, the hazard ratio found in this study was similar to those in previous reports.
キーワード cabergoline levodopa Parkinsonʼs disease motor complications
Amo Type Original Article
発行日 2012-04
出版物タイトル Acta Medica Okayama
出版者 Okayama University Medical School
開始ページ 163
終了ページ 170
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
著作権者 CopyrightⒸ 2012 by Okayama University Medical School
論文のバージョン publisher
査読 有り
PubMed ID 22525474
Web of Science KeyUT 000303175300009